Urea, N-[[(6'R)-6',7'-dihydro-6'-hydroxy-2',4',6'-trimethyl-7'-oxospiro[cyclopropane-1,5'-[5H]inden]-3′-yl]methyl]-N-hydroxy(CAS#924835-67-6)

 Urea, N-[[(6'R)-6',7'-dihydro-6'-hydroxy-2',4',6'-trimethyl-7'-oxospiro[cyclopropane-1,5'-[5H]inden]-3'-yl]methyl]-N-hydroxy(CAS#924835-67-6)

Mechanism: LP-184 is an acylfluoroethylene analogue with potent anticancer activity in ovarian, colon, prostate and pancreatic cell lines, capable of inhibiting tumor growth.

Synthesis method: The synthesis of LP-184 usually involves multi-step organic reactions, and the starting material is usually a compound with a spiro-ring structure, which undergoes a series of reactions such as hydroxyl protection, methylation, and cyclopropanation, and finally introduces functional groups such as urea and hydroxyl groups to obtain the target product. The exact synthetic route will vary depending on laboratory conditions and the choice of starting material.
Physical and chemical properties: At present, there is little data on its specific physical and chemical properties in public information. However, it can be speculated that due to the structure of hydroxyl group, carbonyl group and spirocyclic ring in the molecule, it may have a certain polarity, and its solubility in organic solvents may be good, while its solubility in water is relatively limited. There is no public information on its melting point, boiling point and other data.

Application

LP‑184 (N‑Hydroxy‑N‑(methylacylfulvene)urea, CAS 924835‑67‑6) is a novel, synthetic acylfulvene analog currently in clinical development as a precision oncology agent. This DNA alkylating prodrug is preferentially activated by the oxidoreductase PTGR1, which is overexpressed in various solid tumors, leading to selective DNA damage and apoptosis in cancer cells while sparing normal tissues. LP‑184 demonstrates potent anti‑proliferative activity in ovarian, colon, prostate, pancreatic, and glioblastoma preclinical models, with particular efficacy in tumors harboring homologous recombination deficiency (HRD) or other DNA damage repair (DDR) deficiencies. It forms covalent DNA adducts predominantly at 3’‑adenine, inducing double‑strand breaks and triggering synthetic lethality in DDR‑compromised cells. A Phase 1 first‑in‑human trial is actively evaluating LP‑184 in patients with advanced solid tumors refractory to standard therapies. This compound serves as a valuable research tool for oncology drug discovery, biomarker identification, and DDR mechanism studies. Xinchem offers reliable custom synthesis, custom chemical synthesis, and contract manufacturing of high‑purity LP‑184 (≥98%) with comprehensive analytical characterization, flexible scaling from R&D gram quantities to commercial kilograms. Contact us today for a competitive quote.